Kissei Pharmaceutical Co Ltd - Company Profile

Powered by

All the data and insights you need on Kissei Pharmaceutical Co Ltd in one report.

  • Save hours of research time and resources with
    our up-to-date Kissei Pharmaceutical Co Ltd Strategy Report

  • Understand Kissei Pharmaceutical Co Ltd position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Kissei Pharmaceutical Co Ltd: Overview

Kissei Pharmaceutical Co Ltd (Kissei) discovers, develops, manufactures, and sells pharmaceutical products. The company's pharmaceutical products include urological medicine, metabolic endocrinology medicine, drugs for kidney and dialysis department, drugs for obstetrics and gynecology, ophthalmic medicine and rare disease medicine. It also develops and sells health foods including protein-controlled food, energy supply food, calorie-controlled food, and elderly-controlled food. Kissei conducts research to develop novel drugs and improve existing drugs and provide superior drugs to people worldwide. The company has sales offices across Japan and an overseas subsidiary in New Jersey, the US. Kissei is headquartered in Matsumoto, Japan.

Gain a 360-degree view of Kissei Pharmaceutical Co Ltd and make more informed decisions for your business Gain a 360-degree view of Kissei Pharmaceutical Co Ltd and make more informed decisions for your business Find out more
Headquarters Japan

Address 19-48, Yoshino, Matsumoto-Shi, Nagano, 399-8710


Telephone 81 263 259081

No of Employees 1,795

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange 4547 (TYO)

Revenue (2022) $498.6M 3.2% (2022 vs 2021)

EPS XYZ

Net Income (2022) XYZ -18.5% (2022 vs 2021)

Market Cap* $1.1B

Net Profit Margin (2022) XYZ -21.1% (2022 vs 2021)

* As of and is in US$
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Kissei Pharmaceutical Co Ltd premium industry data and analytics

140+

Clinical Trials

Determine Kissei Pharmaceutical Co Ltd go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

50+

Pipeline Drugs

Identify which of Kissei Pharmaceutical Co Ltd’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

40+

Catalyst Calendar

Proactively evaluate Kissei Pharmaceutical Co Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

40+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Kissei Pharmaceutical Co Ltd’s relevant decision makers and contact details.

30+

Marketed Drugs

Understand Kissei Pharmaceutical Co Ltd’s commercialized product portfolio to stay one step ahead of the market.

20+

Sales & Consensus Forecasts

Understand the current and future drug revenue for Kissei Pharmaceutical Co Ltd and assess market opportunity for new entrants with patient population 8-year forecasts.

7

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Kissei Pharmaceutical Co Ltd’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Pipeline (In-House): Beova
Avacopan/CCX168 - Microscopic polyangiitis/Granulomatosis with polyangiitis Urief
Rovatirelin/ KPS-0373 - Spinocerebellar Ataxia Minirin Melt
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Kissei Pharmaceutical Co Ltd portfolio and identify potential areas for collaboration Understand Kissei Pharmaceutical Co Ltd portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 New Products/Services In July, the company introduced Makya, Iktos Software as a Service Platform for AI-driven drug discovery.
2023 New Products/Services In April, the company launched Oral Platelet Destruction Inhibitor Tavaris Tablets 100mg and 150mg.
2022 New Products/Services In June ,the company launched Tavneos Capsules of 10mg for the treatment of microscopic polyangiitis (MPA) and granulomatosis with polyangiitis.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Kissei Pharmaceutical Co Ltd Tsumura & Co Mochida Pharmaceutical Co Ltd Maruho Co Ltd Kaken Pharmaceutical Co Ltd
Headquarters Japan Japan Japan Japan Japan
City Matsumoto-Shi Minato-Ku Shinjuku-Ku Kita Bunkyo-Ku
State/Province Nagano Tokyo Tokyo Osaka Tokyo
No. of Employees 1,795 4,032 1,529 1,547 1,130
Entity Type Public Public Public Private Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Mutsuo Kanzawa Chief Executive Officer; Chairman Executive Board 2014 -
Yasuo Takehana Chief Operating Officer; Director; President Executive Board 2022 61
Keiji Fukushima Director; Executive Vice President Executive Board 2022 66
Tetsu Takayama Director; Executive Managing Director Executive Board 2022 60
Hiroshi Noake Director; General Manager - Sales and Marketing Division Executive Board 2022 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Kissei Pharmaceutical Co Ltd key executives to enhance your sales strategy Gain insight into Kissei Pharmaceutical Co Ltd key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward